Our Story Samsara BioCapital was founded after years of working in the medical field and investment industry. Our goal is to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance. As a results-driven organization, we are constantly looking for ambitious and visionary partners with the drive and flexibility […]
Investment Type: Venture Capital
Portfolio 4
| Date | Name | Website | Total Raised | Location |
| 18.08.2026 | Abcuro, In... | abcuro.com | $397M | United Sta... |
| 11.07.2023 | @Septerna_... | septerna.com | $290M | United Sta... |
| 10.07.2023 | SpyGlass P... | spyglasspharma.com | $165M | United Sta... |
| 19.07.2022 | Delfi Diag... | delfidiagnostics.com | $325M | United Sta... |
Mentions in press and media 8
| Date | Title | Description |
| 18.08.2026 | Abcuro Raises $66M in Series D Funding | Abcuro, a Newton, MA-based clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, raised $66M in Series D funding. The round was led by New Leaf Ve... |
| 21.06.2026 | Memento Medicines Raises $93 Million Series A For Retinal Disease Therapy | Memento Medicines announced the completion of a $93 million Series A financing round to advance MMT-205, its lead biologic therapy for retinal diseases. The round was co-led by Forbion, RA Capital Management, and Avego BioScience Capital, w... |
| 19.06.2026 | Memento Medicines Raises $93M in Series A Funding | Memento Medicines, Inc., a Boston, MA-based biotech company developing biologic therapies for retinal diseases, raised $93M in Series A funding. The round was led by Forbion, RA Capital Management and Avego BioScience Capital, with particip... |
| 14.11.2023 | Autobahn Labs Announces Key Licensing Milestones in Alliances with Early University Partners | I’m thrilled to see our early partnerships bearing fruit. The two startups, in which we have already invested considerable effort and funding, benefit from exclusive licenses to key university IP.” — Dr. Thomas Novak, Chief Scientific Offic... |
| 08.08.2023 | Autobahn Labs Appoints Chief Executive Officer | Brendan O'Leary - CEO, Autobahn Labs Experienced Life Sciences Executive and Venture Capitalist Dr. Brendan O’Leary Joins Autobahn Labs as CEO We are delighted to welcome Brendan O'Leary to Autobahn Labs. His experience, judgement, and forw... |
| 09.05.2023 | Autobahn Labs Announces Strategic Collaboration with the Salk Institute for Biological Studies | New Collaboration Adds to Autobahn Labs’ Transformative Biotech Incubator Model in California and the Northeast The rigor and potential of research at Salk offers a solid foundation for breakthrough drug discoveries that will enable therapi... |
| 07.06.2022 | ImmunOs Therapeutics raises $74 Million to fund clinical trials | |
| 06.04.2021 | Mineralys Therapeutics Closes $40 Million Series A Funding | Aldosterone has been implicated as an underlying cause of hypertension in upwards of 30 percent of all hypertension patients and as such represents an ideal target for therapeutic intervention in these patients. In a Phase 1 study in health... |